Nederlands
English
Home
Currently selected
Research
Training
Conferences
Business opportunities
About VIB
Donate
Home
>
News
Refine
Theme
About VIB (92)
Arabidopsis (3)
Bioinformatics (11)
Biotech basics (1)
Cancer (69)
Cardiovascular medicine (11)
Cell biology (9)
Grand Challenges (4)
Immunology (32)
Inflammation and immunity (55)
Microbiology (23)
Model Organisms (4)
Mouse (2)
Neuroscience (59)
Plant biology (41)
Proteomics (5)
Research Areas (3)
Science ethics (2)
Structural biology (17)
Systems biology (2)
Yeast (1)
Category
BioInformatics Training and Service facility (1)
Business opportunities (8)
Developmental biology (1)
Event (8)
News (34)
Research services (5)
Page Content Zone 1
News
HDAC6 inhibitors protect against neuronal damage and have therapeutic potential in both neurology and oncology
8 February 2018
Inhibiting HDAC6 improves the structural stability of cells and protects against neuronal damage. Leuven research uncovered that targeting this mechanism could be a promising therapeutic approach for peripheral neuropathies.
A VIB first: Alumna Fabiola Osorio named HHMI international research scholar
7 February 2018
After her return to Santiago de Chile, Fabiola Osorio, an alumna of the VIB-UGent Center for Inflammation Research, was selected to be among the first group of HHMI International Research Scholars.
Science communication: From the lab into the world
6 February 2018
At VIB, we strongly recognize the need to involve as many people as possible in science. On that note, three of our scientists who go the extra mile to get their messages across to a more general public were recently rewarded for their efforts.
3 years of super science: the VIB Conference series in facts and figures
2 February 2018
Since its kick-off back in 2014, VIB conferences have only added to the prestige of the VIB brand, both locally and internationally. Now it’s time to put the numbers – and the events’ numerous fans, partners, sponsors and attendees – in the spotlight.
Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration
1 February 2018
Tau proteins clump together to form neuronal tangles, found in patient brains of more than twenty different neurodegenerative diseases, including various forms of dementia.
Insights from protein pioneer Sir Greg Winter: “ Basic science and applied research always go hand-in-hand.”
27 January 2018
We had the unique opportunity to speak with the front-running father of human antibody research during a visit to the VIB-UGent Center for Inflammation Research.
New collaboration between VIB and Plant Impact Plc: advancing crop enhancement small molecule discovery
23 January 2018
Plant Impact plc and VIB are pleased to announce a new R&D collaboration with focused on furthering research into VIB891, a newly identified small molecule and chemical analogues proven to increase plant biomass.
Stimulating news from the VIB spin-off front
19 January 2018
Our spin-offs are in constant motion.. Let’s take a brief look at what three of them have been up to during the last couple of months.
Scientists discover how treating eczema could also alleviate asthma
19 January 2018
VIB-UGent scientists discovered insights for a possible new therapy for eczema that also reduces the severity of asthma. This is a next step in understanding the relationship between the inflammatory diseases and to developing effective therapies.
Scientists shed light on a key molecular mechanism of autoimmune and inflammatory diseases
17 January 2018
A team of researchers led by prof. Savvas Savvides (VIB-UGent Center for Inflammation Research) has unraveled a crucial aspect of the molecular basis of autoimmune and inflammatory diseases such as psoriasis, rheumatoid arthritis and Crohn’s disease.
Quickscan science topics 2017
13 January 2018
The Innovation Lab brings transformative tech right to the lab
13 January 2018
Technology Innovation is a hot topic, and our own Tech Watch team is working hard to facilitate the ccelerated adoption of disruptive tech across VIB labs and Core Facilities.
VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors
10 January 2018
VIB, the Centre for Drug Design and Discovery of KU Leuven and Galapagos NV signed an exclusive license and collaboration agreement for the development of novel MALT1 inhibitors as therapeutics in inflammatory and/or oncological diseases.
Melanoma research accelerates with two new VIB breakthroughs
29 December 2017
The researchers of the Jean-Christophe Marine lab (VIB-KU Leuven Center for Cancer Biology) are continuously hard at work investigating cancer pathways – focusing particularly on melanoma.
BELNEU: linking neuroscientists with patients for groundbreaking research
18 December 2017
The network of researchers and clinics, called the Belgian Neurology (BELNEU) Consortium is coordinated by Christine Van Broeckhoven and has helped propel dementia and neurodegenerative brain research in Flanders into the global spotlight.
«Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
Next»
Page Content Zone 2
Page Content Zone 3
Get news updates:
Email updates
Follow us on Twitter
Like us on Facebook
RSS